Cargando…

Interleukin 1 receptor antagonist relation to cardiovascular disease risk in patients with rheumatoid arthritis

Interleukin (IL) 1, and its family member, IL-1 receptor antagonist (IL-1ra), are involved in the pathogenesis and inflammation perpetuation of patients with rheumatoid arthritis (RA). Besides, IL-1 has been linked to an increased risk and greater severity of cardiovascular (CV) disease. We aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Almeida-Santiago, Cristina, Quevedo-Abeledo, Juan Carlos, Hernández-Hernández, Vanesa, de Vera-González, Antonia, Gonzalez-Delgado, Alejandra, González-Gay, Miguel Ángel, Ferraz-Amaro, Iván
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372056/ https://www.ncbi.nlm.nih.gov/pubmed/35953706 http://dx.doi.org/10.1038/s41598-022-18128-5

Ejemplares similares

Disease Activity Is More Associated with IL-1 Than with IL-6 in Patients with Rheumatoid Arthritis
por: Almeida-Santiago, Cristina, et al.
Publicado: (2022)

The angiopoietin-like protein 4, apolipoprotein C3, and lipoprotein lipase axis is disrupted in patients with rheumatoid arthritis
por: de Armas-Rillo, Laura, et al.
Publicado: (2022)

Relationship of Blood Inflammatory Composite Markers with Cardiovascular Risk Factors and Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis
por: González-Sierra, Marta, et al.
Publicado: (2023)

Apolipoprotein C-III is linked to the insulin resistance and beta-cell dysfunction that are present in rheumatoid arthritis
por: Martín-González, Candelaria, et al.
Publicado: (2022)

Red Cell Distribution Width Association with Subclinical Cardiovascular Disease in Patients with Rheumatoid Arthritis
por: González-Sierra, Marta, et al.
Publicado: (2023)

The Ratio of Monocytes to HDL-Cholesterol Is Associated with Cardiovascular Risk and Insulin Resistance in Patients with Rheumatoid Arthritis
por: Romo-Cordero, Alejandro, et al.
Publicado: (2023)

Mean Platelet Volume in a Series of 315 Patients with Rheumatoid Arthritis: Relationship with Disease Characteristics, including Subclinical Atherosclerosis and Cardiovascular Comorbidity
por: González-Sierra, Marta, et al.
Publicado: (2023)

The Performance of Vascular Age in the Assessment of Cardiovascular Risk of Patients with Rheumatoid Arthritis
por: Ferraz-Amaro, Iván, et al.
Publicado: (2020)

Disease activity influences the reclassification of rheumatoid arthritis into very high cardiovascular risk
por: Ferraz-Amaro, Iván, et al.
Publicado: (2021)

Incretins in patients with rheumatoid arthritis
por: Tejera-Segura, Beatriz, et al.
Publicado: (2017)

SCORE2 Assessment in the Calculation of Cardiovascular Risk in Patients with Rheumatoid Arthritis
por: Ferraz-Amaro, Iván, et al.
Publicado: (2021)

Relationship between Disease Characteristics and Circulating Interleukin 6 in a Well-Characterized Cohort of Patients with Systemic Lupus Erythematosus
por: Mercader-Salvans, Julia, et al.
Publicado: (2023)

Apolipoprotein C-III in patients with systemic lupus erythematosus
por: Martín-González, Candelaria, et al.
Publicado: (2022)

Correction: Ferraz-Amaro et al. SCORE2 Assessment in The Calculation of Cardiovascular Risk in Patients with Rheumatoid Arthritis. Diagnostics 2021, 11, 2363
por: Ferraz-Amaro, Iván, et al.
Publicado: (2022)

SCORE2 versus SCORE in patients with systemic lupus erythematosus
por: Quevedo-Abeledo, Juan Carlos, et al.
Publicado: (2022)

Key Molecules of Triglycerides Pathway Metabolism Are Disturbed in Patients With Systemic Lupus Erythematosus
por: Quevedo-Abeledo, Juan Carlos, et al.
Publicado: (2022)

Metabolic Syndrome in Rheumatoid Arthritis
por: Ferraz-Amaro, Iván, et al.
Publicado: (2013)

HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis
por: Tejera-Segura, Beatriz, et al.
Publicado: (2017)

Impaired beta cell function is present in nondiabetic rheumatoid arthritis patients
por: Ferraz-Amaro, Iván, et al.
Publicado: (2013)

Vascular Endothelial Growth Factor and Its Soluble Receptor in Systemic Lupus Erythematosus Patients
por: Gómez-Bernal, Fuensanta, et al.
Publicado: (2022)

Serum Levels of Transforming Growth Factor Beta 1 in Systemic Lupus Erythematosus Patients
por: Gómez-Bernal, Fuensanta, et al.
Publicado: (2022)

Relationship between Malondialdehyde Serum Levels and Disease Features in a Full Characterized Series of 284 Patients with Systemic Lupus Erythematosus
por: Merino de Paz, Nayra, et al.
Publicado: (2023)

Transforming growth factor beta 1 is associated with subclinical carotid atherosclerosis in patients with systemic lupus erythematosus
por: Gómez-Bernal, Fuensanta, et al.
Publicado: (2023)

Relationship of Fibroblast Growth Factor 23 Serum Levels with Disease Characteristics in Systemic Lupus Erythematosus Patients
por: Fernández-Cladera, Yolanda, et al.
Publicado: (2023)

Comparison of drug survival rates for tumor necrosis factor antagonists in rheumatoid arthritis
por: Martínez-Santana, Virginia, et al.
Publicado: (2013)

Full characterization of the three pathways of the complement system in patients with systemic lupus erythematosus
por: García-González, María, et al.
Publicado: (2023)

Levels of the Novel Endogenous Antagonist of Ghrelin Receptor, Liver-Enriched Antimicrobial Peptide-2, in Patients with Rheumatoid Arthritis
por: Francisco, Vera, et al.
Publicado: (2020)

HDL Cholesterol Efflux and the Complement System Are Linked in Systemic Lupus Erythematosus
por: García-González, María, et al.
Publicado: (2023)

Proprotein convertase subtilisin/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus
por: Sánchez-Pérez, Hiurma, et al.
Publicado: (2020)

Moderate and High Disease Activity Predicts the Development of Carotid Plaque in Rheumatoid Arthritis Patients without Classic Cardiovascular Risk Factors: Six Years Follow-Up Study
por: Ferraz-Amaro, Iván, et al.
Publicado: (2021)

Management of Cardiovascular Disease Risk in Rheumatoid Arthritis
por: Dessein, Patrick H., et al.
Publicado: (2022)

Blood Composite Scores in Patients with Systemic Lupus Erythematosus
por: Mercader-Salvans, Júlia, et al.
Publicado: (2023)

Genetic Markers of Cardiovascular Disease in Rheumatoid Arthritis
por: Rodríguez-Rodríguez, Luis, et al.
Publicado: (2012)

Implication of new atherosclerotic carotid plaques in the cardiovascular outcome of patients with rheumatoid arthritis
por: González-Gay, Miguel A, et al.
Publicado: (2012)

Protective Role of the Interleukin 33 rs3939286 Gene Polymorphism in the Development of Subclinical Atherosclerosis in Rheumatoid Arthritis Patients
por: López-Mejías, Raquel, et al.
Publicado: (2015)

Inflammation, endothelial function and atherosclerosis in rheumatoid arthritis
por: González-Gay, Miguel A, et al.
Publicado: (2012)

The Clinical Significance of Interleukin–1 Receptor Antagonist +2018 Polymorphism in Rheumatoid Arthritis
por: Ismail, Endom, et al.
Publicado: (2016)

Interleukin-6 (IL-6) Receptor Antagonist Protects Against Rheumatoid Arthritis
por: Li, Songsong, et al.
Publicado: (2016)

Myostatin Levels and the Risk of Myopenia and Rheumatoid Cachexia in Women with Rheumatoid Arthritis
por: Gonzalez-Ponce, Fabiola, et al.
Publicado: (2022)

Atherosclerosis in Rheumatoid Arthritis
por: González-Gay, Miguel A., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_hmv45hkp1i2jogahbi7t5aqn1f